Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Platform
HOTH sits 33% above its 52-week low of $0.489 on light trading volume (0.2× avg).
Summary
Hoth Therapeutics has been awarded a U.S. patent for its HT-KIT oncology platform, covering composition-of-matter and methods for modulating MS4A6A pre-mRNA splicing. This strengthens the intellectual property foundation for its orphan drug-designated program targeting mast cell-driven diseases. The news follows the company's recent announcement of a strategic pivot to AI semiconductor infrastructure, with plans to place its biotechnology pipeline under a separate subsidiary. While a positive development for the biotech assets, the parent company's severe financial distress and new AI focus may temper the immediate market reaction. Hoth expects to finalize its IND submission for HT-KIT in 2026, with first-in-human studies to follow.
At the time of this announcement, HOTH was trading at $0.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $0.49 to $2.12. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.